Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/10486
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tsimihodimos, V. | en |
dc.contributor.author | Kostoula, A. | en |
dc.contributor.author | Kakafika, A. | en |
dc.contributor.author | Bairaktari, E. | en |
dc.contributor.author | Tselepis, A. D. | en |
dc.contributor.author | Mikhailidis, D. P. | en |
dc.contributor.author | Elisaf, M. | en |
dc.date.accessioned | 2015-11-24T16:56:46Z | - |
dc.date.available | 2015-11-24T16:56:46Z | - |
dc.identifier.issn | 1074-2484 | - |
dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/10486 | - |
dc.rights | Default Licence | - |
dc.subject | hypertriglyceridemia | en |
dc.subject | c-reactive protein | en |
dc.subject | fibrinogen | en |
dc.subject | paf-ah | en |
dc.subject | c-reactive protein | en |
dc.subject | platelet-activating-factor | en |
dc.subject | randomized controlled trial | en |
dc.subject | coronary-heart-disease | en |
dc.subject | apparently healthy-men | en |
dc.subject | micronized fenofibrate | en |
dc.subject | cardiovascular-disease | en |
dc.subject | insulin-resistance | en |
dc.subject | gene-expression | en |
dc.subject | receptor-alpha | en |
dc.title | Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values | en |
heal.type | journalArticle | - |
heal.type.en | Journal article | en |
heal.type.el | Άρθρο Περιοδικού | el |
heal.identifier.secondary | <Go to ISI>://000226161600005 | - |
heal.identifier.secondary | http://cpt.sagepub.com/content/9/1/27.full.pdf | - |
heal.language | en | - |
heal.access | campus | - |
heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείας | el |
heal.publicationDate | 2004 | - |
heal.abstract | Background: Atherosclerosis is the leading cause of death in developed countries. Although the mechanisms that underlie this process are not well defined, it has been proposed that atherosclerosis is mainly an inflammatory disease. In this context, a number of inflammatory markers have been studied for their ability to predict future cardiovascular events in asymptomatic individuals or patients with established atherosclerotic disease. Methods and Results: The aim of our study was to evaluate the effect of micronized fenofibrate on serum inflammatory markers, such as C-reactive protein, fibrinogen, and plasma platelet-activating factor acetylhydrolase (PAF-AH) in patients with high triglyceride values. An analysis of baseline values revealed that hypertriglyceridemic patients (n = 58) exhibit an atherogenic phenotype, characterized not only by elevated lipid values but also by high concentrations of serum inflammatory markers. Along with the improvement in serum lipid profile (reduction in triglycerides and total cholesterol, low-density lipoprotein, and non-high-density lipoprotein-cholesterol, with a concomitant increase in high-density lipoprotein-cholesterol levels), fenofibrate administration significantly reduced the values of serum inflammatory markers by 34%, 9.5%, and 24.8% for C-reactive protein, fibrinogen, and plasma PAF-AH, respectively. However, with the exception of PAF-AH, these reductions in inflammatory markers were not correlated with the changes in lipid values. Conclusions: In addition to its well-known hypolipidemic effects, fenofibrate may also possess significant anti-inflammatory properties that can contribute its antiatherogenic effect. | en |
heal.publisher | Sage | en |
heal.journalName | Journal of Cardiovascular Pharmacology and Therapeutics | en |
heal.journalType | peer reviewed | - |
heal.fullTextAvailability | TRUE | - |
Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Tsimihodimos-2004-Effect of fenofibrat.pdf | 1.31 MB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License